Evaluation of a Standardized Strategy for Uveitis Etiological Diagnosis
NCT01162070 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 905
Last updated 2025-09-04
Summary
The Uveitis, the inflammation of the uvea, is a rare disease with an incidence of 52/100,000 inhabitants per year and a prevalence of 115 / 100,000 inhabitants per year.
The causes of uveitis are numerous and include infectious diseases, systemic and neurological diseases, ophthalmic entities, neoplasia, and drug-related reactions. The etiological diagnosis is important both for prognosis and therapeutics.
However, clinical evaluations to establish etiological diagnosis are not standardized. Some authors suggest a minimalist examination, common to all kinds of uveitis. On the other hand, others propose an evaluation guided by the anatomo-clinical type of uveitis.
We conducted a retrospective study to assess the contribution of complementary examinations to etiological determination. In this study, we found that most patients benefited from a wide paraclinical evaluation compared to what is usually described in the literature. Complementary examinations were mostly systematic, without any clinical or ophthalmological elements of orientation. This study highlighted the lack of contribution of some examinations.
Using these results, and the literature analysis, we designed a diagnostic algorithm adapted to the anatomo-clinical type of uveitis.
Moreover, we found that the average cost per patient was estimated at €290.51 with the algorithm compared to €560.83 without it.
We would like to carry out a new study to estimate the efficiency as well as the medico-economic impact of the use of a standardized strategy for the etiological diagnosis of uveitis, compared with a free strategy.
Hypothesis:
* The standardized strategy for the diagnostic of uveitis is at least as efficient as the free one, and costs half as much.
* The examinations prescribed, except for those from the standardized strategy, do not contribute to etiological determination.
Conditions
- Uveitis
Interventions
- OTHER
-
Free strategy
Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
- OTHER
-
Standardized strategy
Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-06-30
- Primary Completion
- 2014-07-31
- Completion
- 2014-07-31
Countries
- France
Study Locations
More Related Trials
-
Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis
NCT05388838 ·Status: RECRUITING ·Phase: NA
-
The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease
NCT00331331 ·Status: COMPLETED
-
Biomarkers in Ocular Inflammation and Uveitis
NCT04690829 ·Status: COMPLETED
-
Incidence of Macular Edema in a Uveitis Population
NCT06686641 ·Status: ACTIVE_NOT_RECRUITING
-
The Cohort Study of Uveitis Patients
NCT05727540 ·Status: RECRUITING
-
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
NCT02258867 ·Status: TERMINATED ·Phase: PHASE3
-
Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients
NCT02252328 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Analysis of Eye Tissue
NCT00001224 ·Status: COMPLETED
-
Efficacy and Safety of Adalimumab in Patients With Active Uveitis
NCT01138657 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
NCT01684345 ·Status: TERMINATED ·Phase: PHASE3
-
Immune Indicators of Uveitis
NCT00089739 ·Status: COMPLETED
-
"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"
NCT05874505 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)
NCT04117698 ·Status: UNKNOWN ·Phase: PHASE3
-
Therapeutic Drug Monitoring-baSed adalimuMab De-escalatiOn in nOn-infecTious cHronic Uveitis
NCT06390436 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
UNICORNS: Uveitis in Childhood Prospective National Cohort Study
NCT05385757 ·Status: ACTIVE_NOT_RECRUITING
-
Apremilast in the Treatment of Uveitis
NCT00889421 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles
NCT07262437 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Leflunomide to Treat Uveitis
NCT00001863 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)
NCT01965145 ·Status: TERMINATED ·Phase: PHASE3
-
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
NCT01526889 ·Status: COMPLETED ·Phase: PHASE2
-
Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study
NCT07105228 ·Status: COMPLETED
-
Treatment FOr Corticosteroid Dependent UveitiS
NCT06258915 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)
NCT03847272 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis
NCT04798755 ·Status: UNKNOWN ·Phase: PHASE3
-
Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
NCT00043667 ·Status: COMPLETED ·Phase: PHASE2